$24.99 $0.83 per serving
Product analysis
Omega-3 2400 mg provides EPA and DHA for triglyceride-related nutritional support at a favorable cost. The oil's chemical form is unspecified, limiting close comparison of absorption potential.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality20
The oil's chemical form is unspecified, limiting absorption comparisons. Identifying EPA and DHA amounts does not resolve how those fats are supplied.
Ingredient Transparency70
The EPA, DHA and other listed amounts are disclosed, with the applicable fat composition details available. The chemical oil form remains unspecified.
Value For Money67
EPA and the combined active omega-3 amount offer favorable value. DHA has a more moderate cost comparison, while the other nutrition entries add little to the value judgment.
Customer Satisfaction72
Customer ratings indicate high satisfaction. The relatively small feedback pool limits how widely that pattern can be applied.
Product Focus65
Triglyceride metabolism provides the clearest role for EPA and DHA. The broader vision and same-day focus purposes are less clearly supported.
- Format
Softgel - Container
- 60 Softgel(s)
- Per serving
- $0.83
- Customer rating
- 4.7 · 102 ratings
Goals
Impact
High effect
Fish Oil · 2400 mg
EPA and DHA can lower triglycerides, which is the main cardiovascular role supported here. Their declared active amounts receive recognition separately; total fish-oil weight does not establish an additional active dose. The trials used particular exposures and populations, so the saved triglyceride finding does not establish prevention of cardiovascular events or improved heart rhythm.
How this product is rated for Cardiovascular Support
Ingredient fit80
The formula contains ingredients relevant to skin nutrition. Their amounts and the presence of other actives determine how focused this finding is.
Goal fit
Relevant skin nutrients sit within a broader formula containing ingredients without an established role for this goal.
Dose adequacy
The disclosed amounts provide partial support; smaller or unresolved quantities limit the amount finding.
Pathways60
The strongest recorded coverage concerns triglyceride metabolism; this is a mechanism finding, not proof of fewer cardiovascular events.
Depth
The strongest recorded coverage concerns triglyceride metabolism; this is a mechanism finding, not proof of fewer cardiovascular events.
Breadth
One cardiovascular mechanism reaches the coverage threshold, with limited coverage of the others.
Evidence83
EPA declared active provides the strongest recognized evidence contribution, subject to the ingredient-specific population and preparation limits.
Evidence strength
EPA declared active provides the strongest recognized evidence contribution, subject to the ingredient-specific population and preparation limits.
Studied preparation
The saved result accepts the relevant preparations, although this does not establish that the finished product matches a skin trial.
Formulation logic100
The included ingredients have no recorded missing partners or configured conflicts. Amount limitations are retained separately.
Partner coverage
No missing required ingredient partner limits the saved finding; this does not establish an added combination benefit.
Conflicts
No configured ingredient conflict was identified in the supplied evaluation.
Effective doses
All ingredients included in this finding meet the saved minimum amount threshold, without proving a clinical response.
Impact
High effect
EPA (Eicosapentaenoic Acid) · 960 mg
EPA provides limited triglyceride-related support, without establishing general prevention of heart attacks or strokes. The 480 mg EPA per serving is distinct from prescription EPA therapy used in selected high-risk patients. DHA is declared under one catalogue identity, while the linked identity remains unresolved and adds no separate contribution; the fish-oil carrier adds no independent benefit.
How this product is rated for Heart Health
Ingredient fit73
The included connections come from EPA (Eicosapentaenoic Acid). Their exposure support does not establish a proven cardiovascular treatment.
Goal fit
The included ingredients are the main assessed connection to heart health, although the product is also linked to other goals.
Dose adequacy
Declared EPA receives partial exposure support; the unresolved linked DHA identity contributes no additional amount support.
Pathways19
The saved findings focus on triglyceride metabolism. They do not establish broad support across the other heart-health pathways.
Depth
The strongest configured connection is to triglyceride metabolism, rather than evidence of a clinical outcome.
Breadth
No configured pathway reaches the saved breadth requirement.
Evidence100
The strongest included evidence contribution comes from EPA (Eicosapentaenoic Acid). Matching a studied preparation does not remove population limits or establish event prevention.
Evidence strength
EPA (Eicosapentaenoic Acid) supplies the strongest included evidence contribution, without establishing cardiovascular-event prevention.
Studied preparation
The included preparations meet the saved study-matching check, which does not establish that this finished product or serving prevents cardiovascular events.
Formulation logic100
The counted ingredients meet the minimum amount requirement, with no missing required partner or matched conflict.
Partner coverage
No counted ingredient lacks a required partner; this finding does not imply an additional combination benefit.
Conflicts
No configured ingredient conflict was matched in the supplied facts.
Effective doses
All counted ingredients meet the saved minimum amount requirement, which is distinct from a proven clinical treatment dose.
Impact
High effect
EPA (Eicosapentaenoic Acid) · 960 mg
DHA is important to retinal structure, while EPA has an anti-inflammatory rationale. Their presence does not establish improved routine adult vision: the supplied clinical context does not show an overall AMD advantage from added omega-3s or better dry-eye outcomes than placebo. The separately declared DHA and EPA amounts describe these ingredients without treating total fish oil as either active.
How this product is rated for Eye Health
Ingredient fit69
The formula includes nutrients related to vision, with differing amount support.
Goal fit
Several ingredients relate to vision, within a formula that also addresses other functions.
Dose adequacy
The known contributing amounts provide partial support against the amount references; these references do not establish effective clinical doses.
Pathways53
The main represented area is retinal and lens antioxidant defense. The connection is concentrated in one area rather than broad visual-performance support.
Depth
The strongest represented area is retinal and lens antioxidant defense; this describes ingredient roles rather than demonstrated visual improvement.
Breadth
The represented areas are retinal and lens antioxidant defense.
Evidence79
The nutrient contributions have specific population and outcome limits; normal functions do not establish improved vision with adequate intake.
Evidence strength
EPA (Eicosapentaenoic Acid) provides the leading retained contribution, with the population and outcome limits described for that ingredient.
Studied preparation
Preparation support is incomplete across the contributing ingredients; declared active amounts do not establish a matching studied preparation.
Formulation logic100
No configured ingredient conflict or missing required partner was identified; this does not establish synergy or clinical effectiveness.
Partner coverage
No required ingredient partner is missing among the retained contributions; this does not establish extra benefit from combining them.
Conflicts
No configured ingredient conflict was identified.
Effective doses
The retained contributions meet the amount threshold used here; that threshold is not proof of clinical benefit.
DHA (Docosahexaenoic Acid) Not classified
No linked studies yet.
Impact
Moderate effect
Fish Oil · 2400 mg
EPA and DHA may help lower inflammation markers, including CRP and certain inflammatory signalling proteins. Both fatty acids are declared here, although changes in these markers don't tell you whether you'll notice less pain or other symptoms. The fish-oil weight and other fat-panel amounts shouldn't be treated as extra EPA or DHA.
How this product is rated for Inflammation
Ingredient fit60
EPA and DHA are both declared, providing the relevant fatty acids.
Goal fit
EPA and DHA are both declared, providing the relevant fatty acids.
Dose adequacy
The serving declares 480 mg EPA and 360 mg DHA separately; fish-oil and other fat amounts are not additional EPA or DHA.
Pathways13
EPA and DHA relate mainly to fatty-acid substances involved in inflammation, with a smaller connection to inflammatory gene signals.
Depth
EPA and DHA relate mainly to fatty-acid substances involved in inflammation, with a smaller connection to inflammatory gene signals.
Breadth
The connection is concentrated in fatty-acid processes and inflammatory gene signals, rather than spanning all inflammation-related processes.
Evidence70
Marine EPA and DHA have a connection to lower inflammation markers; noticeable symptom benefits remain less clear. Both fatty acids are identified separately; generic fish-oil weight adds no separate active amount.
Evidence strength
Marine EPA and DHA have a connection to lower inflammation markers; noticeable symptom benefits remain less clear.
Studied preparation
Both fatty acids are identified separately; generic fish-oil weight adds no separate active amount.
Formulation logic100
The relevant ingredient can act without an additional partner. No particular ingredient conflict is identified.
Partner coverage
No additional partner ingredient is required for the relevant ingredient’s individual role.
Conflicts
No particular ingredient conflict is identified.
Effective doses
The serving declares 480 mg EPA and 360 mg DHA separately; fish-oil and other fat amounts are not additional EPA or DHA.
Impact
Moderate effect
The declared 360 mg DHA and 480 mg EPA provide omega-3 support relevant to brain health over time. Their cognitive evidence concerns repeated intake and selected populations, so a dependable same-day concentration benefit is uncertain.
How this product is rated for Mental Focus
Ingredient fit58
Focus-related ingredients are part of a broader-purpose mix. Several relevant amounts fall below the saved reference levels, limiting the contribution expected from one serving.
Goal fit
Focus-related ingredients are part of a broader-purpose mix.
Dose adequacy
Several relevant amounts fall below the saved reference levels, limiting the contribution expected from one serving.
Pathways45
The strongest saved connection is synaptic plasticity and neuroprotection, with partial coverage. The saved findings identify 1 sufficiently covered focus mechanism, so support remains concentrated rather than broad.
Depth
The strongest saved connection is synaptic plasticity and neuroprotection, with partial coverage.
Breadth
The saved findings identify 1 sufficiently covered focus mechanism, so support remains concentrated rather than broad.
Evidence56
EPA (Eicosapentaenoic Acid) provides the strongest saved evidence among ingredients meeting the amount threshold. Ingredient-specific limitations still matter for everyday focus. Only part of the relevant ingredient mix matches the saved preparation criteria, which limits how closely the evidence applies.
Evidence strength
EPA (Eicosapentaenoic Acid) provides the strongest saved evidence among ingredients meeting the amount threshold. Ingredient-specific limitations still matter for everyday focus.
Studied preparation
Only part of the relevant ingredient mix matches the saved preparation criteria, which limits how closely the evidence applies.
Formulation logic100
The saved findings identify no missing required ingredient partner. No configured ingredient conflict was found in the supplied record.
Partner coverage
The saved findings identify no missing required ingredient partner.
Conflicts
No configured ingredient conflict was found in the supplied record.
Effective doses
All ingredients counted in the saved amount check reach its minimum threshold; that threshold is not a guarantee of noticeable benefit.
DHA (Docosahexaenoic Acid) Not classified
No linked studies yet.
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Calories | 35 Calorie(s) | |
Calories from Fat | 25 Calorie(s) | |
Total Fat | 3 Gram(s) | |
Saturated Fat | 1 Gram(s) | |
Polyunsaturated Fat | 1 Gram(s) | |
Monounsaturated Fat | 0.5 Gram(s) | |
Cholesterol | 25 mg | |
Carbohydrates | 1 Gram(s) | |
Protein | 1 Gram(s) | |
Fish Oil concentrate | 2400 mg | |
Eicosapentaenoic Acid | 960 mg | |
Docosahexaenoic Acid | 720 mg |
EPA (Eicosapentaenoic Acid) · 960 mg OverallScore67
Each serving provides 960 mg EPA and 720 mg DHA. The whole-product serving costs about $0.83.
How this ingredient is rated
Active Ingredient Quality & Bioavailability58
The molecular form of EPA is not identified in the saved information. The 960 mg EPA is about 40% of the 2400 mg fish oil per serving.
Molecular Form and Bioavailability
The molecular form of EPA is not identified in the saved information.
EPA Concentration Density
The 960 mg EPA is about 40% of the 2400 mg fish oil per serving.
Oxidation Protection
Tocopherol is recorded as an antioxidant; actual oxidation protection was not measured by the evaluation.
Dose, Safety & Label Transparency71
Each serving provides 960 mg EPA and 720 mg DHA. Qualifying purification or testing claims are not established in the saved information.
Absolute EPA Dose per Serving
Each serving supplies 960 mg EPA.
EPA-Centric Ratio
Each serving has 960 mg EPA and 720 mg DHA, with somewhat more EPA than DHA.
Purity and Contaminant Testing
The saved information does not establish a qualifying purification or contaminant-testing claim; this does not establish contamination.
Value80
Based on the whole-product serving price, the cost is about $0.87 per gram of EPA.
Price per Gram of EPA
Based on the whole-product serving price, the cost is about $0.87 per gram of EPA.
Fish Oil · 2400 mg OverallScore53
DHA · 720 mg OverallScore53
Alternative products
Report alternatives
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127 477 Participants.
- Impact of omega-3 fatty acids on hypertriglyceridemia, lipidomics, and gut microbiome in patients with type 2 diabetes.
- A systematic review of fish-oil supplements for the prevention and treatment of hypertension.
- Effects of fish oil-derived fatty acids on suboptimal cardiovascular health: A multicenter, randomized, double-blind, placebo-controlled trial.
- Effect of High-Dose Marine Omega-3 Fatty Acids on Atherosclerosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
- Dietary omega-3 LCPUFA intake in the prevention of neovascular age-related macular degeneration: a systematic review and meta-analysis.
- Dietary omega-3 polyunsaturated fatty acids and fish intake and risk of age-related macular degeneration.
- Dietary fatty acid intake, plasma fatty acid levels, and the risk of age-related macular degeneration (AMD): a dose-response meta-analysis of prospective cohort studies.
- Dietary ω-3 fatty acid and fish intake and incident age-related macular degeneration in women.
- Can Omega-3 Fatty Acids Serve as a Preventive Strategy for Age-Related Macular Degeneration? A Systematic Review and Meta-Analysis.
- Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.
- Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS).
- Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: a meta-analysis.
- Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease.
- Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.
- Dose-dependent effects of fish oil on cardio-metabolic biomarkers in healthy middle-aged and elderly Chinese people: a double-blind randomized controlled trial.
- Eicosapentaenoic acid supplementation alleviates pruritus, enhances skin moisture, and mitigates depression in maintenance hemodialysis patients.
- Lowering effects of fish oil supplementation on proinflammatory markers in hypertension: results from a randomized controlled trial.
- The effects of ω-3 fish oil emulsion-based parenteral nutrition plus combination treatment for acute paraquat poisoning.
- Effects of Omega-3 Fatty Acid Intake in Patients Undergoing Dialysis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.